Get Blog Posts By Email
Total Website Visits:993,844
Category Archives: 2014
Not long ago, I came across a website called Prostatesnatchers, written by a prominent West coast urologist, Dr. Mark Scholz and Ralph Blum. Recent posts addressed such topics as: a) radiation for PSA-relapsed prostate cancer; an alternative to lifelong Lupron more »
It’s Christmas 2014 and a New Year 2015!!! The time of year when a man’s thoughts turn to prostate cancer, right? Unfortunately, it seems that is true for those of us who have this condition. Just recently, I saw an more »
The Prostate Cancer Research Institute (PCRI) has listed four (4) Phase 2 or Phase 3 clinical trials which are currently recruiting patients. These trials all involve immunotherapeutic agents. The first is a Phase 3 trial of ProstAtak® coupled with standard more »
Urinary incontinence is a major complication of radical prostatectomy. According to the November 9th Johns Hopkins Health Alerts (Prostate Disorders), incidence of serious incontinence from surgery at medical centers of excellence is low, around 3% whereas from overall national patient more »
In our current disposable society, I am sure that we can all think about specific items that we would have no use for or difficult times in our lives that we would rather not re-live. But the truth is more »
In the last few years, several new therapeutic agents have been approved for treating various aspects of prostate cancer. Now research also needs to focus on the timely utilization of these agents either individually or in combination and at which more »
1) A “Calculator” to Predict Biopsy Outcomes; 2) Understanding the TNM Staging System Upon Prostate Cancer Diagnosis.
1) Researchers at the University of Texas Health Sciences Center in San Antonio have developed a “calculator” to predict probabilities of biopsy results based upon data such as PSA, age, race, results of digital examination and family history. To access more »
Monitoring Emergence of Treatment-Resistant Prostate Cancer by Measuring Circulating Tumor DNA Levels.
Androgen deprivation (hormonal) therapy is often administered to men with advanced prostate cancer. However, after a period of time genetic mutations can occur in the prostate cells which then promote tumor growth. A new way to monitor how a man’s more »
Testosterone (androgen)-depleting therapies are usually the first line of defense for men with newly-diagnosed or recurrent prostate cancer. But resistance to these therapies develop over time which leaves the patient and physicians with a number of choices as to the more »
Exelixis, the biotechnology firm developing the metastatic medullary thyroid cancer drug, cabozantinib, in the treatment of a variety of cancers, recently announced disappointing Phase III clinical trial results for the use of cabozantinib in the treatment of metastatic, hormone-resistant (refractory) more »